Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemogenovatucel-T
- Development stage
- Phase 2
- Lead developer
- Gradalis
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
Gemogenovatucel-T is a first-in-class, personalized autologous tumor cell vaccine immunotherapy designed for the treatment of advanced ovarian cancer and other solid tumors. It is engineered using a dual bi-shRNA platform to knock down furin (a convertase involved in activating immunosuppressive TGFβ-1 and TGFβ-2) while simultaneously augmenting expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), a potent immune system stimulator. This approach aims to reduce tumor-mediated immune suppression and enhance recruitment of immune effector cells at the vaccination site. The therapy uses each patient’s own harvested tumor tissue to create an individualized vaccine targeting unique clonal neoantigens present in their cancer. Gemogenovatucel-T has demonstrated significant improvements in recurrence-free survival and overall survival—especially among patients with BRCA wild-type or homologous recombination proficient (HRP) ovarian cancer with high clonal tumor mutation burden—in randomized controlled trials[1][2][6][7][9].
- Brand names
- Vigil
- Other names
- FANGgemogenovatucel-TVigil
02
Targets
Furin
Beyond the preview
Go deeper on gemogenovatucel-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemogenovatucel-T.